Ireland
--:--IST
Priya Life Science Clinical trial register
Trackers› Clinical trials› Follicular Lymphoma
Clinical trial register · China

Follicular Lymphoma Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19212 matching records held by the registry are in this view. Synced 10 Nov 2026, 03:17 UTC
19212
Studies in scope
all four open statuses
11805
Recruiting now
open to new participants
2029
Lead sponsors
across recruiting studies
Top sites
Beijing 9 Xiamen 6 Zhengzhou 6 Guangzhou 6 Shanghai 6
Narrow the registerReset
Recruitment status
Phase
Site location
Beijing9 Xiamen6 Zhengzhou6 Guangzhou6 Shanghai6
All 32 locations
Target enrolment
to

Follicular Lymphoma trials in China

28 of 19212 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Merck Sharp & Dohme LLC
Phase 2/3
960
Beijing, Shanghai
2026-06-22
Not yet open
Pomalidomide Plus Anti-CD20 Antibody and Prednisone in Frontline Indolent B-Cell Lymphoma
NCT07609446Indolent Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Indolent Mantle Cell Lymphoma
The First Affiliated Hospital of Soochow University
Observational
30
Suzhou
2026-05-01
Not yet open
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
27
Shenzhen, Zhengzhou, Nanchang, Jinan, Tianjin
2026-04-15
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
80
Tianjin
2026-04-10
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
34
Tianjin
2025-12-25
Not yet open
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Phase 3
228
Beijing, Chongqing, Lanzhou, Guangzhou, Guiyang, Haikou, Harbin, Zhengzhou
2025-11
Recruiting
The First Affiliated Hospital with Nanjing Medical University
Not applicable
15
Nanjing
2025-07-15
Not yet open
JWCAR239 in Patients With B Cell Non-Hodgkin Lymphoma
NCT07024147B-Cell Non-Hodgkin Lymphoma, Large B Cell Diffuse Lymphoma, Follicular Lymphoma, Marginal Zone B Cell Lymphoma
Peking University Cancer Hospital & Institute
Phase 1
20
Beijing
2025-07-01
Not yet open
Zhejiang Cancer Hospital
Phase 2
58
Hangzhou
2025-05-01
Recruiting
The First Affiliated Hospital of Xiamen University
Phase 2
30
Xiamen
2025-02-08
Recruiting
Tianjin Medical University Cancer Institute and Hospital
Phase 2
20
Tianjin
2024-12-20
Not yet open
Ruijin Hospital
Phase 2
66
Shanghai
2024-12-01
Active, closed
Zhengzhou University
Observational
37
Zhengzhou
2024-05-01
Not yet open
Jiangsu HengRui Medicine Co., Ltd.
Phase 2
105
Beijing
2024-04
Recruiting
The First Affiliated Hospital of Xiamen University
Phase 2
39
Xiamen
2024-03-31
Not yet open
Relmacabtagene Autoleucel in Hematologic Malignancies
NCT06142188Lymphoma, B-Cell, Large B-cell Lymphoma, Follicular Lymphoma
Shanghai Ming Ju Biotechnology Co., Ltd.
Observational
150
Beijing
2023-12-28
Recruiting
Lenalidomide Combined With G-CHOP in the Treatment of Newly Diagnosed DLBCL With FL
NCT06151080DLBCL - Diffuse Large B Cell Lymphoma, Follicular Lymphoma
The First Affiliated Hospital of Xiamen University
Phase 2
38
Xiamen
2023-11-22
Recruiting
Chidamide Combined With Linperlisibon for the Treatment of Refractory/Relapsed Follicular Lymphoma
NCT06158386Follicular Lymphoma, Refractory B-Cell Lymphoma, Relapsed Non-Hodgkin Lymphoma
The First Affiliated Hospital of Xiamen University
Phase 2
33
Xiamen
2023-11-22
Recruiting
Ruijin Hospital
Observational
332
Shanghai
2023-06-01
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Observational
50
Tianjin
2022-11-01
Active, closed
A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)
NCT05458297Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma, Richter Transformation Lymphoma
Merck Sharp & Dohme LLC
Phase 2
189
Beijing, Guangzhou, Zhengzhou, Wuhan, Suzhou, Xuzhou, Nanchang, Chuangchun
2022-07-21
Recruiting
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
NCT05006716B-cell Malignancy, Marginal Zone Lymphoma, Follicular Lymphoma, Non-Hodgkin Lymphoma
BeOne Medicines
Phase 1/2
689
Beijing, Guangzhou, Zhengzhou, Yichang, Shanghai, Tianjin, Wenzhou
2021-09-13
Recruiting
Sun Yat-sen University
Phase 2
32
Guangzhou
2021-08-01
Active, closed
Epizyme, Inc.
Phase 3
599
Fuzhou, Xiamen, Guiyang, Zhejiang, Shijiazhuang, Zhengzhou, Changsha, Changchun
2020-06-11
Active, closed
A Long-term Extension Study of PCI-32765 (Ibrutinib)
NCT01804686Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma
Janssen Research & Development, LLC
Phase 3
539
Beijing, Chengdu, Fuzhou, Guangzhou, Hangzhou, Shanghai, Shanxi, Suzhou
2013-09-09
Rows per page Showing 1–28 of 28
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 10 November 2026. https://priyalifescience.com/clinical-trials-china/condition/follicular-lymphoma

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,212 studies in total at the last sync on 10 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 28 of those studies listing the condition Follicular Lymphoma.

How many Follicular Lymphoma trials are recruiting in China?

14 of the 28 studies on this page are recruiting new participants as of the 10 Nov 2026, 03:17 UTC sync. A further 8 have not yet opened recruitment, 6 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Follicular Lymphoma), 28 studies
PhaseStudiesRecruitingShare
Phase 213846.4%
Observational5217.9%
Phase 35117.9%
Phase 1/2217.1%
Not applicable113.6%
Phase 1103.6%
Phase 2/3113.6%

Most active sponsors

Lead sponsors with the most studies (Follicular Lymphoma)
Lead sponsorStudiesRecruiting
Institute of Hematology & Blood Diseases Hospital, China43
The First Affiliated Hospital of Xiamen University44
Merck Sharp & Dohme LLC21
Ruijin Hospital21
BeOne Medicines11
Celgene11
Epizyme, Inc.10
Hoffmann-La Roche10
Incyte Corporation10
Janssen Research & Development, LLC10
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.